These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 26032778

  • 1. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS.
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [Abstract] [Full Text] [Related]

  • 2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 7. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F, Del Vecchio L, Violo L, Pontoriero G.
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 May; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
    Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroishi K, Yamaguchi Y.
    Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
    [Abstract] [Full Text] [Related]

  • 14. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S, Yamanaka S, Koreeda D, Yashiro M, Shigematsu T.
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG, Elisaf MS.
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [Abstract] [Full Text] [Related]

  • 17. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY, de Borst MH, Ter Wee PM, Vervloet MG, NIGRAM Consortium.
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.